Orchard Therapeutics Limited has agreed a rebate with health insurers in Germany for its one-off gene therapy, Libmeldy (atidarsagene autotemcel), for the treatment of metachromatic leukodystrophy (MLD). The company’s chief commercial officer, Braden Parker, shed some light on the agreement and what the company plans to do next to get Libmeldy to patients.
Orchard Secures New Libmeldy Price In Germany
Orchard Therapeutics says it is confident in the success of its gene therapy for MLD, which has secured the highest possible benefit rating from the German authorities.
More from Europe
• By
England’s health technology assessment institute, NICE, is looking to “reimagine” its evaluation process with the help of AI, rather than just using this technology to speed up its existing processes.
• By
In a historic move for Africa, five products have been backed for approval via a pilot that tested a continental listing process.
• By
Pharmaceutical companies are being encouraged to reach out to NICE in relation to its HTA Innovation Lab, which provides a sandbox environment in which the health technology assessment body can test new methods of evaluating “innovative and disruptive” therapies.
• By
The weight management drug, Mysimba, continues to demonstrate a positive benefit-risk balance but the data available are not sufficient to fully determine the cardiovascular safety beyond 12 months. Meanwhile, Currax this month announced the publication of a peer-reviewed study of Mysimba that followed patients for over 4.7 years and found no evidence of excess cardiovascular risk.
More from Geography
• By
The loss of policy analyst, legal, project manager and social scientist positions has experts wondering if the Trump Administration is eyeing a broader effort to limit DTC advertising. The OPDP layoffs are expected to result in delayed reviews of promotional pieces.
• By
In a historic move for Africa, five products have been backed for approval via a pilot that tested a continental listing process.
• By
CMED, which sets medicine prices in Brazil, has published the maximum price adjustment index for 2025.